Trial · NCT07893158
A Study of Nicotine Orodispersible Tablet on Craving Relief of Male and Female Smoker Volunteers
NCT07893158, Phase 2, Recruiting, McNeil AB
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Nicotine Orodispersible Tablet on Craving Relief of Male and Female Smoker Volunteers. Trials, record NCT07893158. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07893158
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Nicotine Orodispersible Tablet on Craving Relief of Male and Female Smoker Volunteers
- NCT number
- NCT07893158
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 280 participants, estimated
- Lead sponsor
- McNeil AB
- Conditions
- Smoking Cessation, Nicotine Replacements Therapy
- Interventions
- Nicotine Mint Oro Dispersible Tablet (Nic ODT), Placebo Oro Dispersible Tablet (Placebo ODT)
- First posted
- 2026-10-23
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Visual Analog Scale (VAS) score change | 2 minutes, 1 minute, 0.75 minutes (45 seconds) and 0.5 minutes (30 seconds) after start of IP administration. | The change from baseline in momentary urge-to-smoke VAS score (scale of 0: no urge to smoke to 100: extremely high urge to smoke). Baseline is defined as the mean of the three pre-dose VAS assessments collected at -5, -3, and -1 minute prior to treatment administration. |
| Secondary | Visual Analog Scale (VAS) score change | At 0.25 (15 seconds), 3, 5, and 10 minutes after start of administration. | The change from baseline in momentary urge-to-smoke VAS score (scale of 0: no urge to smoke to 100: extremely high urge to smoke). Baseline is defined as the mean of the three pre-dose VAS assessments collected at -5, -3, and -1 minute prior to treatment administration. |
| Secondary | Occurrence of self-reported and observed AEs | From signing of informed consent through study completion, up to 46 days | |
| Secondary | The time from administration to the sensation of disintegration of Nic ODT. | Day 1, after completion of PD assessments: from start of Nic ODT administration up to approximately 5 minutes | Time from start of Nic ODT administration (tablet placed on the tongue) to the participant's first signal of perceived onset of disintegration. |
| Secondary | The time for total disintegration of Nic ODT. | Day 1, after completion of PD assessments: from start of Nic ODT administration up to approximately 5 minutes | Time from start of Nic ODT administration to the participant's signal of complete disintegration, confirmed by mouth check. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07893158
GET https://conductscience.org/api/trials/v1/NCT07893158/registered